MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • CytRx, Inc. (CYTR) Hosting Conference Call At 10:30 AM EST Today For Global Phase 2b Clinical Trial Data Of Aldoxorubicin 0 comments
    Dec 11, 2013 3:06 PM | about stocks: CYTR

    CytRx, a biopharmaceutical research and development company that specializes in oncology treatments, will be hosting a conference call today, Wednesday, December 11, 2013, at 10:30 am EST to announce a significant company milestone.

    The company will be discussing and answering questions regarding top-line results of its global Phase 2b clinical trial of its chemotherapeutic drug, aldoxorubicin, as a first-line treatment for advanced soft tissue sarcomas (NYSEMKT:STS) versus the widely used chemotherapeutic agent doxorubicin. At 8:00 am EST this morning, a press release was made available detailing the results of this clinical trial.

    The conference call can be accessed by dialing 888-463-4383 (U.S. and Canada) or 706-679-5355 (international callers). A webcast will be accessible in the Investor Relations section of the company's website, found at: cytrx.com

    A replay of this call and webcast will become available around two hours after the conference call has officially ended. To access the replay, investors and attendees are advised to dial 855-859-2056 (U.S. and Canada) or 404-537-3406 (international callers) and to enter the conference ID number: 19821609.

    Currently CytRx is focusing its primary attention on the development of aldoxorubicin, its improved version of the widely-used chemotherapeutic treatment doxorubicin. Soft tissue sarcoma is a cancer that appears in muscle, fat, blood vessels, tendons, fibrous tissues, and connective tissue. It has been observed to be capable of arising anywhere in the human body in a person of any age. Over 30 types of this cancer have been identified. The extent of this cancer's influence is also quite extensive, as the American Cancer Society estimates that there are an additional 10,500 cases that are diagnosed in the U.S. each year.

    More in-depth scientific information regarding aldoxorubicin and its cancer-ending potential can be found at: cytrx.com/aldoxorubicin

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CYTR
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.